{"organizations": [], "uuid": "bfb449d191a21f912ea0479ace4531e5b84584f9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/europe", "section_title": "European Stock Market News | Reuters.com", "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-very-con/brief-roche-holding-ag-ceo-says-very-confident-we-can-grow-in-spite-of-the-entry-of-biosimilars-idUSFWN1S307K", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T14:30:00.000+03:00", "replies_count": 0, "uuid": "bfb449d191a21f912ea0479ace4531e5b84584f9"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-very-con/brief-roche-holding-ag-ceo-says-very-confident-we-can-grow-in-spite-of-the-entry-of-biosimilars-idUSFWN1S307K", "ord_in_thread": 0, "title": "BRIEF-Roche Holding AG CEO Says Very Confident We Can Grow In Spite Of The Entry Of Biosimilars", "locations": [], "entities": {"persons": [{"name": "roche", "sentiment": "negative"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "brief-roche holding ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "roche holding ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - Roche Holding AG:\n* CEO SAYS CONFIDENT OF ROCHEâ€™S ABILITY TO CONTINUE GROWTH BEYOND 2018 DESPITE BIOSIMILAR ENTRIES\n* CEO SAYS INCREASE IN GUIDANCE IS FOR BOTH SALES AND EPS * DRUG DIVISION CHIEF SAYS RITUXAN DECLINE IN EUROPE WAS BROADLY EXPECTED, SEES EUROPEAN EROSION TO CONTINUE IN SECOND HALF OF YEAR COUPLED WITH ARRIVAL OF FIRST HERCEPTIN COPY\n* DRUG DIVISION CHIEF SAYS STILL CONFIDENT CAN COMPENSATE FOR BIOSIMILAR EROSION OF OLDER DRUGS\n* DRUG DIVISION CHIEF SEES CONTINUED STRONG OCREVUS GROWTH * CEO SAYS WE ARE ON THE CONSTANT LOOKOUT FOR NEW TECHNOLOGIES, WE SCREEN THE MARKET FOR OPPORTUNITIES\n* CEO SAYS CONTINUES TO LOOK FOR BOLT-ON ACQUISITIONS\n* CEO SAYS TYPICALLY DOES NOT MAKE SENSE TO PURSUE LATE-STAGE TRANSACTIONS THAT END UP IN BIDDING PROCESS, CLEARLY HAS FOCUS ON EARLIER STAGE ASSETS\n* CEO SAYS HAS 15 NEW MOLECULAR ENTITITES IN LATE STAGE PORTFOLIO\n* CEO SAYS VERY CONFIDENT WE CAN GROW IN SPITE OF THE ENTRY OF BIOSIMILARS Source text for Eikon: (Reporting by John Miller)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T14:30:00.000+03:00", "crawled": "2018-04-26T09:47:58.014+03:00", "highlightTitle": ""}